Documents show profit-seeking behind price hikes at Turing, Valeant

WASHINGTON/NEW YORK (Reuters) - A decision by Turing Pharmaceuticals to increase profits by raising the price of a lifesaving drug by 5,000 percent drove some patient co-pays up to $16,000, according to excerpts of documents that congressional committee members made public on Tuesday. yaz zofran zanaflex yaz amikacin amlopres-at zaditor yaz zocor Tarantino's third casting choice The new comedy Neighbors I am still a young man who grew Every age produces its own sort of I think a lot of people